1. De-escalation of Intensive Therapies

As serum potassium stabilizes and ongoing losses resolve, intravenous (IV) potassium infusions and continuous cardiac monitoring can be methodically reduced to prevent rebound dyskalemia and arrhythmias.

Criteria for Tapering IV Potassium

1. Serum K⁺ is stable within the target range (e.g., 3.5–5.0 mEq/L) on two consecutive measurements at least 4 hours apart.
2. The primary cause of ongoing potassium loss has resolved (e.g., diuretics held or reduced, gastrointestinal losses corrected).
3. The electrocardiogram (ECG) shows no signs of significant hypo- or hyperkalemia (e.g., no U-waves, no peaked T-waves).

Infusion Rate Ceilings and Monitoring

• Peripheral line: Infusion rate should not exceed 10 mEq/hr. Continuous ECG monitoring is optional at this rate but recommended if other risk factors for arrhythmia are present.
• Central line: Infusion rates up to 20 mEq/hr are possible, but continuous ECG monitoring is required for any rate exceeding 10 mEq/hr.

Weaning Continuous Cardiac Monitoring

Telemetry can be stepped down from continuous monitoring to intermittent strips and then to daily checks as clinical and biochemical stability is demonstrated.

• Stop Continuous ECG When: Serum K⁺ remains in the target range for ≥12 hours, the ECG is normal for at least 12 hours, and no other indications for monitoring (e.g., acute coronary syndrome, other ongoing electrolyte shifts) are present.
• Stepwise Weaning: A safe approach is to transition from continuous monitoring to intermittent 4-hour strips, then to a once-daily spot ECG, before discontinuing monitoring entirely.

2. Conversion to Enteral Potassium Supplementation

Once gastrointestinal function returns, transitioning to enteral potassium chloride (KCl) is preferred. It offers predictable absorption and allows for smoother adjustments to serum levels compared to intermittent IV boluses.

Dose Conversion and Titration

A pragmatic rule of thumb is that 10 mEq of enteral KCl raises serum K⁺ by approximately 0.1 mEq/L in a patient without significant ongoing losses. A safe starting point is to calculate 50% of the patient’s total IV potassium requirement from the previous 24 hours and administer that amount enterally, divided into doses every 6 to 8 hours.

Enteral Access and Formulation Considerations

• Formulations: Immediate-release (IR) tablets peak in 1–2 hours. Sustained-release (SR) tablets reduce GI irritation but are less titratable for acute adjustments.
• Administration: Avoid jejunal or duodenal delivery of concentrated solutions. Use gastric access and dilute with water flushes. Separate KCl administration from enteral feeding by at least 30 minutes before and after to prevent binding.
• Interactions: Gastric pH modifiers like PPIs or H₂ blockers can slow the dissolution of IR tablets. Never crush SR KCl tablets, as this destroys the release mechanism and increases the risk of mucosal injury.

3. Mitigation of Post-ICU Syndrome (PICS)

Post-ICU Syndrome (PICS) describes the persistent physical, cognitive, and psychological deficits that can follow a critical illness. Proactive, multidisciplinary care can mitigate its severity. Electrolyte stability, particularly normokalemia, is a key component of physical recovery.

The ABCDEF Bundle for ICU Liberation

The ABCDEF bundle is a proven, evidence-based framework for improving ICU outcomes and reducing the incidence of PICS. Each component is critical and should be assessed daily.

4. Discharge Planning & Interprofessional Handoff

A comprehensive discharge plan is crucial to prevent readmissions and recurrent dyskalemia. This requires meticulous medication reconciliation, patient education, and a clear outpatient monitoring strategy communicated effectively among all care providers.

Medication Reconciliation

Identify and address all medications that affect potassium homeostasis:

• Potassium-Wasting: Loop and thiazide diuretics.
• Potassium-Sparing: RAAS inhibitors (ACEi, ARBs, ARNIs), mineralocorticoid receptor antagonists (MRAs), and potassium-sparing diuretics.
• Other: Laxatives, potassium binders (both old and new).
• Strategy: Adjust diuretic doses based on current volume status and renal function. Consider using newer potassium binders like patiromer or sodium zirconium cyclosilicate to enable the continuation of life-saving RAAS inhibitors in patients with CKD or heart failure.

Patient and Caregiver Education

Use the teach-back method to ensure understanding of key concepts:

• Dietary Targets: Provide clear guidance on dietary potassium (e.g., 2,000–3,000 mg/day for CKD stages 3–5).
• Warning Signs: Educate on symptoms of both hypokalemia (muscle cramps, weakness, fatigue) and hyperkalemia (palpitations, tingling, chest pain).
• Medication Adherence: Explain the role of each medication and the importance of taking them as prescribed.

Outpatient Monitoring and Communication

• Follow-up Labs: High-risk patients (e.g., those on multiple K⁺-affecting drugs, with fluctuating renal function) should have a lab check within one week of discharge.
• Interprofessional Handoff: Use a structured tool like SBAR (Situation, Background, Assessment, Recommendation) to communicate potassium trends, medication changes, and follow-up plans to the primary care provider, nephrologist, and pharmacist.